Table 2.
Summary of papers included in the review (n = 15)
| Author (year of publication) | Outcome | Country | Study design | Total patients in study (n) | CSM/BM (n) | BM + R (n) | UM (n) | UM + R (n) | Limitations |
|---|---|---|---|---|---|---|---|---|---|
| Baker (2021)32 | Patient-reported | US, CA, GB, AUS | Cross-sectional, qualitative and quantitative | 931 | 748 | – | 183 | – | Included BM for bilateral cancer and prophylaxis. |
| Brown (2018)31 | Patient-reported | US | Qualitative | 16 | 16 | – | – | – |
Does not mention BRCA or family history exclusion NB: part of larger study of 68 participants, only BM cohort (n = 16) analyzed in this paper Extrapolation of qualitative data from this paper is limited as only SGM people were included |
| Delierel (2021)18 | Patient-reported | US | Cross-sectional, quantitative | 1525 | 106 | 414 | 109 | 219 |
Included cohort with family history of BC 677 underwent BCS |
| Eck (2014)19 | Clinical | US | Retrospective cohort, quantitative | 352 | 39 | 108 | 114 | 91 | |
| Huang (2018)21 | Clinical | US | Retrospective cohort, quantitative | 471 | 17 | 259 | 82 | 113 | Included women with BRCA mutations |
| Huang (2020)20 | Patient-reported | US | Cross-sectional, quantitative | 55 | NS | NS | NS | NS | Does not mention BRCA or family history exclusion |
| Huang (2018)22 | Patient-reported | US | Cross-sectional, quantitative | 94 | NS (BM ± recon = 52) | NS | NS (UM ± recon = 42) | NS | Few BM patients without reconstruction (21.3% of total participants had no reconstruction) |
| Hwang (2016)23 | Patient-reported | US | Cross-sectional, quantitative | 3977 | 326 | 1270 | 889 | 1490 | Does not mention BRCA or family history exclusion |
| Lim (2021)24 | Patient-reported | CA | Prospective cohort, quantitative | 475 | 16 | 75 | 113 | 69 |
BREAST-Q score differences may not be clinically significant 202 underwent unilateral lumpectomy |
| Miller (2013)25 | Clinical | US | Retrospective cohort, quantitative | 600 | 21 | 188 | 177 | 214 | Does not mention BRCA or family history exclusion |
| Osman (2013)26 | Clinical | US | Retrospective cohort, quantitative | 4219 | 497 | – | 3722 | – | Data were extracted by coding from large database |
| Pinell-White (2014)27 | Clinical | US | Retrospective cohort, quantitative | 446 | 28 | 146 | 99 | 173 | Included cohort with family history of BC. Only 2 complications in BM group |
| Rosenberg (2020)28 | Patient-reported | US | Prospective cohort, quantitative | 826 | NS (BM ± recon = 375) | NS | NS (UM ± recon = 197) | NS | Included cohort with family history of BC and BRCA mutation |
| Schroeder (2020)29 | Clinical | US | Retrospective cohort, quantitative | 12,959 | 95 | 1289 | 6223 | 5352 | Does not mention BRCA or family history exclusion |
| Sharpe (2014)30 | Clinical | US | Retrospective cohort, quantitative | 39,0712 | NS (BM ± recon = 75437) | NS | NS (UM ± recon = 315278) | NS | Does not mention BRCA or family history exclusion. Data extracted by coding from large database |
CSM contralateral symmetrizing mastectomy, BM bilateral mastectomy, R reconstruction, UM unilateral mastectomy, US United States, CA Canada, GB Great Britain, AUS Australia, NB nota bene (please note) BC breast cancer, NS not stated, SGM sexual and gender minority, BCS breast-conserving surgery